Menu
Close
.svg)
Every ASCO has its data moments. But #ASCO26 felt bigger than a single readout.
This year’s meeting underscored a broader shift in oncology: science is expanding what is possible, but translating that progress into clinical practice is becoming far more complex.
Across tumor types and treatment modalities, familiar narratives were being rewritten. Targets once considered undruggable are moving closer to the center of oncology innovation. Treatment decisions are becoming less about choosing the “strongest” option and more about selecting the right approach for the right patient at the right time. And personalization is no longer limited to biomarkers; it increasingly includes how patients experience, tolerate, and manage therapy.
Three themes rose to the top:
For years, RAS was the classic “undruggable” target. At ASCO 2026, that narrative changed in a way that was impossible to miss.
The most talked-about moment of the meeting was RASolute 302, the Phase 3 study of daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma. The results were striking: median overall survival (OS) reached 13.2 months with daraxonrasib versus 6.7 months with chemotherapy in the overall study population.
In a disease area where progress has historically been incremental, that magnitude of benefit was deeply meaningful. The daraxonrasib OS data drew a standing ovation, a rare reaction at ASCO, and one that reflected the scale of unmet need in pancreatic cancer as much as the strength of the data.
But the excitement was not just about one therapy or one tumor type. It was about what this moment signaled for the broader RAS field.
Daraxonrasib’s activity across patients, regardless of identified RAS mutation status, distinguishes it from narrower mutation-specific approaches and reinforces the potential of multi-selective RAS targeting as a clinically meaningful strategy.
As Dr. Stephen Fesik stated during the session “The KRAS Journey: Perseverance Pays Off,” “The age of the undruggable is over.” Modern fragment-based screening, AI-driven drug design, and biomarker-directed trials are making traditionally difficult targets increasingly viable in the clinic.
RAS may be the most visible example, but it is unlikely to be the last. For a target once considered out of reach, RAS now feels very much at the center of oncology innovation.
Another major theme was the growing complexity of oncology decision-making.
This came through clearly in the newly added case-based panels, which gave experts and audience members a platform to discuss how they approach complex clinical scenarios in real time. It was also reflected in sessions like “Is the Juice Worth the Squeeze?” and the debate-style discussion “When Less Is More,” which explored the nuances of targeted therapy and immunotherapy combinations in NSCLC.
The underlying question was not simply whether a regimen works. It was whether it is worth it for a given patient, in a given context, at a given point in the treatment journey.
The oncology landscape is no longer defined by a simple tradeoff between the “biggest gun” and the “better tolerated” option. ADCs, immunotherapies, targeted therapies, bispecifics, and novel combinations are bringing meaningful advances, but they also come with distinct toxicity profiles, monitoring requirements, sequencing questions, and patient-management considerations.
In many settings, oncologists are making decisions without clean head-to-head comparisons. As a result, the clinical calculus increasingly includes not only efficacy, but also AE profile, reversibility, monitoring burden, patient comorbidities, practice logistics, nurse familiarity, and the patient’s own preferences and tolerance for risk.
For oncology launch teams, this has implications for narrative development.
A strong efficacy story is necessary, but it is no longer sufficient. Successful adoption depends on whether the broader care ecosystem feels prepared to use the therapy well. That includes oncologists, nurses, advanced practice providers, caregivers, and patients.
In this environment, toxicity management materials are no longer downstream support assets. They are core to the value proposition. They need to be practical, easy to use, and tested with the people who will rely on them in real-world care. In particular, testing patient-facing materials with nurses can reveal the questions, friction points, and communication gaps that may not surface in physician-only research.
Personalized medicine is usually discussed in terms of biomarkers and therapeutic targets. But at ASCO this year, another form of personalization stood out: personalizing care around adverse event management.
As treatments become more effective but also more specialized, the patient experience of therapy becomes a bigger part of the decision. In the absence of definitive sequencing data, oncologists are weighing practical and human factors more heavily: how AEs present, how manageable they are, how quickly they need to be addressed, and how prepared patients feel to communicate early with their care team.
This theme was reinforced across multiple educational sessions. One session, “From Novel Agents to Novel Adverse Events,” brought together patient, ophthalmologist, and dermatologist perspectives on the impact and management of ocular and cutaneous toxicities associated with newer systemic anticancer therapies. Another, “Management of Bispecific Antibody Toxicities,” focused on CRS/ICANS, cytopenias, and long-term toxicities associated with these agents.
Across presentations, case discussions, and panels, the conversation was not simply, “Which therapy is most effective?” It was also, “What can this specific patient tolerate? What are they worried about? How confident are they in managing side effects? What support do they need to stay on therapy?”
The implication is clear: patient support cannot be generic. AE education needs to be specific, actionable, and confidence-building. Patients need to know not only what could happen, but what to do, when to act, and whom to contact.
The future of oncology is not just more targeted therapy. It is more targeted support.
ASCO 2026 highlighted a powerful tension shaping the next era of oncology.
Science is expanding what is possible. Narratives that once felt fixed, around undruggable targets, treatment escalation, and what it means to personalize care, are changing quickly.
But the path from clinical progress to real-world impact is becoming more complex. The next wave of oncology innovation will be defined not only by therapies that deliver meaningful benefit, but by care teams that feel equipped to manage them and patients who feel informed, supported, and confident throughout treatment.
